These challenges led CF NBS laboratories [45,46] to consider biotechnologies that would greatly expand the CFTR panel after two major advances that facilitated such a change—the advent of next generation sequencing (NGS) [47] and the knowledge gained from the CFTR2 project [48,49]. This evidence concerns the gene CFTR and cystic fibrosis.